Kolexia
Giuily-Guigui Nathalie Médecine générale
Giuily-Guigui Nathalie
Médecine générale
Hôpital Beaujon
Clichy, France
22 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Hépatite Hépatite C Hépatite chronique Hépatite C chronique Hépatite B Hépatite B chronique Fibrose Carcinomes Maladies du foie

Collaborateurs

Voir plus
Castelnau-Marchand Corinne
Castelnau-Marchand Corinne
Hôpital Beaujon, Clichy, France
Boyer-Darrigrand Nathalie
Boyer-Darrigrand Nathalie
Hôpital Beaujon, Clichy, France
Marcellin Patrick
Marcellin Patrick
Hôpital Beaujon, Clichy, France
Asselah Tarik
Asselah Tarik
Hôpital Beaujon, Clichy, France

Industries

Voir plus
Abbvie
3 collaboration(s)
Dernière en 2023
B3TSI
2 collaboration(s)
Dernière en 2021
SOS Oxygène
1 collaboration(s)
Dernière en 2021
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort.
Hepatic medicine : evidence and research   18 décembre 2017
Higher occurrence of HCC in DAAs therapy than in Peg-IFN based therapy in patient with chronic hepatitis C related cirrhosis
The 68th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2017   01 octobre 2017
Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients.
Journal of viral hepatitis   04 juillet 2016
The baseline combination of HBcrAg and HBsAg titers enhance treatment outcome and HBsAg loss predictions in HBeAg negative chronic hepatitis B patients treated with pegylated interferon alfa-2a or PegIFN plus Tenofovir-disoproxil-fumarate
The 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015   07 octobre 2015
Baseline HBsAg titer allows identification of patients that will benefit from pegylated interferon therapy and experience an HBsAg loss
The 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015   07 octobre 2015
P0800 : Effectiveness and safety of combination new regimens based on Sofosbuvir (SOFO) with Ribavirin (RBV), Daclatasvir (DAC) or Simeprevir (SIM) in difficult patients to treat infected with chronic hepatitis C (CHC)
Abstracts of The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver   01 avril 2015
P0860 : The impact of interferon-free regimens on employment rate during treatment in patients with chronic hepatitis C
Abstracts of The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver   01 avril 2015
Delay presentation to care is an independent prognostic factor for clinical outcomes in patients with chronic hepatitis C
The 65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2014   01 octobre 2014
Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C.
Liver international : official journal of the International Association for the Study of the Liver   22 novembre 2011
Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
Hepatology (Baltimore, Md.)   21 avril 2010